Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 Synthesis  




2 References  













Luzindole






●日本語
 ●Српски / srpski
 ●Srpskohrvatski / српскохрватски
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Luzindole
Clinical data
ATC code
  • None
Legal status
Legal status
  • In general: non-regulated
Identifiers

  • N-[2-(2-benzyl-1H-indol-3-yl)ethyl]acetamide

CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H20N2O
Molar mass292.382 g·mol−1
3D model (JSmol)

  • O=C(NCCc2c1ccccc1[nH]c2Cc3ccccc3)C

  • InChI=1S/C19H20N2O/c1-14(22)20-12-11-17-16-9-5-6-10-18(16)21-19(17)13-15-7-3-2-4-8-15/h2-10,21H,11-13H2,1H3,(H,20,22)

  • Key:WVVXBPKOIZGVNS-UHFFFAOYSA-N

Luzindole (N-0774), (N-acetyl-2-benzyltryptamine), is a drug used in scientific research to study the role of melatonin in the body. Luzindole acts as a selective melatonin receptor antagonist,[1] with approximately 11- to 25-fold greater affinity for the MT2 over the MT1 receptor.[2][3] In animal studies, it has been observed to disrupt the circadian rhythm as well as produce antidepressant effects.[2][4]

Synthesis

[edit]

Although the "hydrogen bomb" method was reported as 54% yield by Dubococvich, Boehringer Sohn achieved 96% for this step. The difference is that B.I. conducted their hydrogenation under normal pressure at 50°C for 5 hours, whereas Dubocovich conducted theirs at 100 lbs/in2 hydrogen heated to 35°C. This proves that the hydrogenation step proceeds favorably under milder conditions.

Patents:[5][6][7]

The Pictet–Spengler reaction between tryptamine [61-54-1] (1) and benzaldehyde gives 1-Phenyl-tetrahydrocarboline [3790-45-2] (2). Catalytic hydrogenation leads to 2-Benzyltryptamine [22294-23-1] (3). Acylation with acetic anhydride only gave 21% yield of Luzindole (4).

Luzindole synthesis 2:[8]

2-iodoaniline [615-43-0] (1) Propargylbenzene [10147-11-2] (2) 2-(3-phenylprop-1-ynyl)aniline, PC85868179 (3) 2-benzylindole [3377-72-8] (4) 1-Dimethylamino-2-nitroethylene [1190-92-7] (5) (6)

One pot Luzindole synthesis:[9]

References

[edit]
  1. ^ Dubocovich ML (September 1988). "Luzindole (N-0774): a novel melatonin receptor antagonist". The Journal of Pharmacology and Experimental Therapeutics. 246 (3): 902–10. PMID 2843633.
  • ^ a b Dubocovich ML, Yun K, Al-Ghoul WM, Benloucif S, Masana MI (September 1998). "Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms". The FASEB Journal. 12 (12): 1211–20. doi:10.1096/fasebj.12.12.1211. PMID 9737724. S2CID 566199.
  • ^ Browning C, Beresford I, Fraser N, Giles H (March 2000). "Pharmacological characterization of human recombinant melatonin mt(1) and MT(2) receptors". British Journal of Pharmacology. 129 (5): 877–86. doi:10.1038/sj.bjp.0703130. PMC 1571913. PMID 10696085.
  • ^ Dubocovich ML, Mogilnicka E, Areso PM (July 1990). "Antidepressant-like activity of the melatonin receptor antagonist, luzindole (N-0774), in the mouse behavioral despair test". European Journal of Pharmacology. 182 (2): 313–25. doi:10.1016/0014-2999(90)90290-M. PMID 2168835.
  • ^ Margarita L. Dubocovich, et al. WO1989001472A1 ().
  • ^ Margarita L. Dubocovich, et al., U.S. patent 5,283,343 (1994 to Discovery Therapeutics Inc).
  • ^ Schroeder Dr Hans-D, et al. DE1445516 (1968 to CH Boehringer Sohn AG and Co KG).
  • ^ Tsotinis, Andrew; Afroudakis, Pandelis (2008). "Melatonin Receptor Antagonist Luzindole: A Facile New Synthesis". Letters in Organic Chemistry. 5 (6): 507–509. doi:10.2174/157017808785740561. ISSN 1570-1786.
  • ^ Righi, Marika; Topi, Francesca; Bartolucci, Silvia; Bedini, Annalida; Piersanti, Giovanni; Spadoni, Gilberto (2012). "Synthesis of Tryptamine Derivatives via a Direct, One-Pot Reductive Alkylation of Indoles". The Journal of Organic Chemistry. 77 (14): 6351–6357. doi:10.1021/jo3010028.

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Luzindole&oldid=1228280190"
    Categories: 
    ●Drugs not assigned an ATC code
     ●Acetamides
     ●Tryptamines
     ●Melatonin receptor antagonists
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●Drugs with non-standard legal status
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Articles containing unverified chemical infoboxes
      


    ●This page was last edited on 10 June 2024, at 11:06 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki